Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan Aesthetic Medicines Head Moatazedi Moves To Emerging Competitor Evolus

Executive Summary

David Moatazedi is leaving behind the aesthetic medicines group at Allergan to run the newly public, aesthetics-only firm Evolus, where US and EU approval of the Botox competitor DWP-450 (prabotulinumtoxinA) is imminent and the new CEO says the opportunity is unparalleled.


Related Content

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It
Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends
Mylan Set To Develop Biosimilar Botox In Deal With Revance
Revance's Long-Acting RT002 Will Have Slow-Moving Impact On Allergan
Pipeline Watch: Topline Phase III Results For Tenapanor, Abemaciclib
Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business
Daewoong Strikes New Deal For Botox Rival


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts